Deals

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications
HKG: 2096Lynk Pharmaceuticals

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications

Lynk Pharmaceuticals announced the expansion of its commercialization partnership with Simcere Pharmaceutical Group Limited (HKG: 2096) for zemprocitinib, its in‑house developed, highly selective oral second‑generation JAK1 inhibitor. Under the new…

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Shanghai Pharma X842 Deal Termination with Sinorda
HKG: 2607SHA: 601607

Shanghai Pharma X842 Deal Termination with Sinorda

Mirxes XtalPi AI Platform Targets Asian GI Cancers
AIHKG: 2228

Mirxes XtalPi AI Platform Targets Asian GI Cancers

Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal
ChemPartner PharmatechHKG: 2257

Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal

OTR Therapeutics Series-A Raises $100M for Neurology Pipeline
BiotechFinance

OTR Therapeutics Series-A Raises $100M for Neurology Pipeline

Show More